5 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors

4. Insmed Incorporated (NASDAQ:INSM)

PAI’s Stake Value: $171,304,000
Percent of 13F Portfolio: 9.44%
Number of Hedge Fund Holders: 22

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical organization. Patients with severe and uncommon diseases benefit from the company’s research and development.

Palo Alto Investors manages 6.02 million shares in Insmed Incorporated (NASDAQ:INSM), worth over $171.30 million, representing 9.44% of their portfolio. The hedge fund has increased stakes in the firm by 4% in the second quarter of 2021. Palo Alto Investors is the most significant stakeholder of Insmed Incorporated (NASDAQ:INSM).